|
|
||||||||

,


U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21701 ,
Naval Medical Research Institute, Bethesda, Maryland 20814 ,
Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 20205
Malaria was transmitted to six normal human volunteers by mosquitoes infected from cultured gametocytes of Plasmodium falciparum. This method, which offers advantages over other methods of infecting volunteers, will be useful for evaluating the efficacy of human malaria vaccines.
Accepted for publication September 4, 1985.
This article has been cited by other articles:
![]() |
F. Sanderson, L. Andrews, A. D. Douglas, A. Hunt-Cooke, P. Bejon, and A. V. S. Hill Blood-stage Challenge for Malaria Vaccine Efficacy Trials: A Pilot Study with Discussion of Safety and Potential Value Am J Trop Med Hyg, June 1, 2008; 78(6): 878 - 883. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Dunachie, M. Walther, J. E. Epstein, S. Keating, T. Berthoud, L. Andrews, R. F. Andersen, P. Bejon, N. Goonetilleke, I. Poulton, et al. A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge. Infect. Immun., October 1, 2006; 74(10): 5933 - 5942. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Walther, F. M. Thompson, S. Dunachie, S. Keating, S. Todryk, T. Berthoud, L. Andrews, R. F. Andersen, A. Moore, S. C. Gilbert, et al. Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein. Infect. Immun., May 1, 2006; 74(5): 2706 - 2716. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Webster, S. Dunachie, J. M. Vuola, T. Berthoud, S. Keating, S. M. Laidlaw, S. J. McConkey, I. Poulton, L. Andrews, R. F. Andersen, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara PNAS, March 29, 2005; 102(13): 4836 - 4841. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |